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The introduction of the implantable cardioverter-
defibrillator (ICD) for primary prevention of sudden
cardiac death has led to an important reduction in mor-
tality in patients with impaired left ventricular ejection
fraction (LVEF) [1, 2]. Consequently, current clinical
guidelines recommend ICD implantation for primary
prevention in patients with an LVEF below 30–40 %
[3]. Although the landmark trials upon which these
guidelines are based have utilised various imaging mo-
dalities to assess LVEF, two-dimensional (2D) echocar-
diography has been most frequently used to enrol pa-
tients. Furthermore, in clinical practice 2D echocardiog-
raphy is still most commonly performed for this pur-
pose, as it is inexpensive and readily available. In
recent years, however, cardiovascular magnetic reso-
nance imaging (CMR) has emerged as the preferred
modality to quantify left ventricular volumes and LVEF
due to its high reproducibility and accuracy. As such,
CMR is often referred to as the gold standard for LVEF
assessment [4]. The question arises, whether these im-
aging modalities are interchangeable for evaluating the
eligibility of ICD therapy. This issue becomes particu-
larly relevant in patients with borderline LVEF values
(30–40 %) for primary prevention of sudden cardiac
death when LVEF is virtually the only parameter to
guide such a decision.
The study performed by De Haan et al. published in
the current issue of the Netherlands Heart Journal in-
cluded 152 patients who were referred for primary
prevention ICD implantation [5]. All patients underwent
LVEF assessment by 2D echocardiography as well as
CMR within three months prior to device implantation.
De Haan et al. report significantly lower values of left
ventricular volumes by 2D echocardiography, which on
average yielded a higher LVEF of 6.6 %. Although this
percentage might sound trivial, from a clinical point of
view such an apparent small difference can have great
consequences (see Fig. 1). In fact, when taking the
most utilised LVEF cut-off value of 35 % by 2D
echocardiography to determine device eligibility, 28 %
of patients were reclassified when CMR was used as a
reference. Apparently, the choice of imaging has a
substantial impact on the decision process of selecting
appropriate patients for ICD implantation. Obviously,
this raises concern and leads to the question which
modality to choose. When stakes are that high for the
care of our patients, knowledge on the background and
characteristics of such imaging modalities becomes
imperative.
The lack of uniformity between imaging modalities
to assess LVEF has been well documented. Although
comparative studies have shown some discrepancies,
most of the data suggest that LVEF tends to be highest
when utilising 2D echocardiography and subsequently
gradually declines with CMR and nuclear ventriculog-
raphy, respectively [6]. The quality of echocardiogra-
phy heavily relies on an adequate acoustic window and
bi-plane Simpson’s delineation of the endocardial con-
tours may not be obtained in as many as 30 % of
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patients. Moreover, 2D echocardiography is based on
geometric assumptions of the left ventricle, which
poses a source of error in patients with heart failure
and LV remodelling. Even with sufficient image qual-
ity, the reproducibility of 2D echocardiography has
proven to be inferior to CMR [7]. Consequently, many
centres nowadays consider CMR to be the imaging
modality of choice to screen patients for ICD eligibil-
ity. In line with the current results of De Haan et al.,
Joshi and colleagues have also recently highlighted that
CMR guided ICD therapy results in an approximately
25 % augmented implantation rate as compared with
echocardiography [8]. Although long-term follow-up
and comparison of the event rate of echo vs. CMR
driven ICD therapy is lacking, one could logically
hypothesise that appropriate ICD therapy for ventricu-
lar arrhythmic events will decrease for CMR based
implantation when identical LVEF cut-off values are
applied. As a consequence, health care costs will
steadily rise whereas the relative benefit for our pa-
tients diminishes. As correctly pointed out by De Haan
et al., the LVEF threshold to guide ICD therapy when
utilising CMR should be redefined and will likely need
to be adjusted to lower levels.
So what should our practice be in the meantime? As
current clinical guidelines for ICD implantation are
predominantly based on studies using 2D echocardiog-
raphy, it could be argued that this type of imaging
should be preferred to practice evidence-based medi-
cine. Indeed, the ACC/AHA/ESC 2006 guidelines for
ICD implantation actually recommend echocardiogra-
phy for the assessment of left ventricular function
[3]. It is of interest to note that the more recent
ACC/AHA/HRS 2008 guidelines have nuanced this
recommendation and no longer specify an imaging
modality to assess LVEF, as long as it is ‘… the most
clinically accurate and appropriate in their institution’
[9]. The current data from De Haan et al. remind us
that different imaging modalities should certainly not
be considered interchangeable and we should be aware
what lies beneath the obtained results of a certain
requested test to guide the clinical course of our pa-
tients. Even though it is clear that CMR holds great
potential to act as gatekeeper for ICD therapy, caution
on its interpretation is warranted. Future studies should
focus on the clinical consequences of CMR based
evaluation of ICD eligibility for primary prevention
of sudden cardiac death.
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Fig. 1 A 67-year-old patient with ischaemic cardiomyopathy who was
screened for ICD implantation for primary prevention of sudden cardiac
death. No arrhythmias were documented and the patient did not show
signs of heart failure. Both 2D echocardiography and CMR were per-
formed, which yielded a difference in LVEF of 10 % (44 vs. 34 %,
respectively). Based on echocardiographic analysis, ICD implantation
should not have been performed, yet CMR drove the decision to implant
the device. To date, 2 years after implantation, no ventricular arrhythmic
events have occurred
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